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Background
Acid suppression treatment has been linked to an
increased incidence of allergy in adults. We evaluate how
ranitidine, widely used off-label to treat gastro-esophageal
reflux symptoms in neonates, may impair peptic digestion,
increasing the risk of sensitization to digestion-labile food
antigens and thus increasing the prevalence of atopy.
Methods
We carried out a retrospective review of preterm infants
of between 26 and 37 weeks gestation admitted over a
two-year period between April 2008 and March 2010.
Those preterm infants treated with the H2-receptor
antagonist ranitidine for more than seven days were
identified. A control group of preterm infants who did
not receive treatment was selected by matching gesta-
tion, birth weight and disease severity using a validated
scoring method. We analysed both maternal data (mode
of delivery, use of intrapartum antibiotics, prolonged
rupture of the membranes, sepsis) and neonatal data
(birth weight, gestation, interventions, sepsis, type of
feeding and neonatal complications). Information con-
cerning the development of atopy in children in both
groups, as well as any family history of atopy, was
obtained through a simple questionnaire.
Results
There were 38 infants in the group treated with ranitidine
(exposure group) and 37 in the control group. There was
no significant difference in perinatal characteristics and
neonatal morbidity between the two groups. The preva-
lence of atopy was 39% in the exposure group and 47% in
the control group (p= 0.57). Subgroup analysis showed the
prevalence of milk allergy was 17% in both groups and
Non Significant (NS); the prevalence of atopic eczema was
18% (exposure) vs 45% (control) (p = <.001); and the pre-
valence of recurrent wheeze or asthma was 13% (exposure)
vs 11% (control) (NS). Prevalence of other food allergies
was very low and comparable. No difference in the family
history of atopy was observed.
Conclusions
Ranitidine treatment in preterm infants did not increase
the overall prevalence of atopy at two years of age but a
significantly lower prevalence of atopic dermatitis was
observed in the group treated with ranitidine.
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